LP-935509 NEW
| Price | $33 | $47 | $76 |
| Package | 1mg | 2mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: LP-935509 | CAS No.: 1454555-29-3 |
| Purity: 99.64% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | LP-935509 |
| Description | LP-935509 is a selective, brain-permeable, small molecule competitive inhibitor of articulin-2-associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM. LP-935509 is a potent inhibitor of BIKE (IC50 of 14 nM) and a moderate inhibitor of GAK (IC50 of 320±40 nM). |
| In vitro | METHODS: The effects of LP-935509 on the activities of the two most closely related kinases, BIKE and GAK kinases, were evaluated; the ability of 1 μM LP-935509 to inhibit the binding of 389 kinases to ATP-binding probes was measured. RESULTS LP-935509 is a potent inhibitor of BIKE (IC50= 14 nM) and a modest inhibitor of GAK (IC50= 320 ± 40 nM), and LP-935509 inhibited the binding of more than 70% of the probes to 13 kinases, including BIKE. [1] |
| In vivo | METHODS: LP-935509 (10, 30, and 60 mg/kg) was administered orally (10 ml/kg), and Von Frey tests were performed at 0, 30, and 120 min after administration. RESULTS Oral administration of LP-935509 resulted in a dose-dependent reduction in phase II paw withdrawal that was significantly lower than that in vehicle-treated animals (Figure 3A). In particular, 30 mg/kg and 60 mg/kg of LP-935509 resulted in a significant reduction in pain behavior. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 175 mg/mL (441.43 mM), Sonication is recommended. |
| Keywords | orally active | AP2-associated kinase 1 | Inhibitor | brain-penetrant | SARS coronavirus | LP 935509 | pain | spinal nerve ligation | SARS-CoV | Cyclin G-associated Kinase (GAK) | Antinociceptive | AAK1 | LP935509 | infection | chronic constriction injury | inhibit | streptozotocin | formalin | Auxilin 2 | LP-935509 | ATP-competitive | SNL | Adaptor-associated Kinase 1 |
| Inhibitors Related | Nafamostat mesylate | Piceatannol | SBC-115076 | Fasudil hydrochloride | Camostat mesylate | SRPIN340 | HA-1004 | FOY 251 | SGC-AAK1-1 | BMT-124110 Formate | Benzamidine hydrochloride | Cetraxate hydrochloride |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Neuronal Signaling Compound Library | Kinase Inhibitor Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2180.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $2120.00/25mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $0.00/1kg |
Nanjing Fred Technology Co., Ltd
|
2024-01-04 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY